Toonaangevende academische en industriële cluster om 80% van de ziektegerelateerde menselijke eiwitten aan te pakken die momenteel niet geneesbaar zijn
WALTHAM, Massachusetts – (BUSINESS WIRE) – PerkinElmer, Inc., een wereldleider die zich inzet voor innovatie voor een gezondere wereld, heeft vandaag aangekondigd dat het optreedt als leverancier en mede-ontwikkelaar van testen, instrumentoplossingen en expertise voor het PROXIDRUGS Consortium die zich richt op onderzoek naar nabijheidsmedicijnen of PROTAC’s (PROteolysis Targeting Chimeras). PROTAC’s zijn een nieuwe klasse geneesmiddelen die gebruik maken van het lichaamseigen recyclingsysteem van celeiwitten om ziekten te bestrijden door gebruik te maken van de 80% van de ziektegerelateerde eiwitten die momenteel niet worden gebruikt door de huidige beschikbare therapieën. Onder leiding van de Goethe Universiteit in Frankfurt, Duitsland, omvat het consortium onderzoekers van de Technische Universiteit van Darmstadt, het Fraunhofer Instituut voor Translationele Geneeskunde en Farmacologie en wereldwijde farmaceutische bedrijven gevestigd in de Rijn-Main-regio van Frankfurt.
PerkinElmer Supports PROXIDRUGS Consortium Aimed at Advancing Targeted Protein Degradation/PROTAC Drugs
Leading academic and industry cluster to help address 80% of disease-relevant human proteins currently undruggable
WALTHAM, Mass.–(BUSINESS WIRE)– PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it is serving as a provider and co-developer of assays, instrument solutions and expertise for the PROXIDRUGS Consortium which is zeroing in on research for proximity drugs or PROTACs (PROteolysis Targeting Chimeras). PROTACs are a new class of drugs that take advantage of the body’s own cell protein recycling system to fight disease by tapping into the 80% of disease-relevant proteins that are currently untargeted by today’s available therapeutics. Led by Goethe University in Frankfurt, Germany, the Consortium includes researchers from the Technical University of Darmstadt, the Fraunhofer Institute for Translational Medicine and Pharmacology, and global pharmaceutical companies based in Frankfurt’s Rhine-Main region.
The research project, starting October 2021, aims to streamline novel drug target validation by putting disease-relevant proteins in close proximity with key enzymes (such as E3 ligases) so that they can be marked for destruction and recycled by the cells’ natural shredding capabilities.
To help in these efforts, PerkinElmer will provide the consortium with no-wash AlphaLISA® and HTRF® immunoassay technologies and expertise in protein labeling as well as assay design; EnVision® multimode plate readers; high content imaging technologies such as the Opera Phenix® and Operetta CLS™ platforms; and data analysis and informatics tools like TIBCO Spotfire® software. These PerkinElmer offerings will give PROXIDRUGS scientists a highly sensitive and accelerated discovery platform with rich data delivery and high throughput for both live and dead cell research.
Commenting on this groundbreaking research and collaboration, Alan Fletcher, SVP of Life Sciences at PerkinElmer said, “With only 20% of disease-relevant proteins currently being targeted by classical, small molecule drugs, new research approaches, such as PROTAC drug discovery, hold immense and exciting potential. We are delighted to be able to contribute our expertise and technologies to assist in the innovative work of the PROXIDRUGS Consortium as it seeks new ways to help unlock and tackle the vast majority of proteins behind widespread diseases such as cancer, neurological disorders, and cardiovascular, inflammatory and infectious conditions.”
The PROXIDRUGS consortium is led by Ivan Đikić of Goethe University Frankfurt, who also commented on the importance of forming alliances across organizations to help advance novel drug discovery and development: “Successful translation of biomedical research requires strong collaboration and convergence of industry and academic expertise. Our work with PerkinElmer within the PROXIDRUGS consortium is a good example of that. PerkinElmer’s expertise and innovation in assay development is of utmost importance and will help to create new insights for our discovery efforts.”
The PROXIDRUGS Consortium was recently selected for funding by the German Federal Ministry of Education and Research as part of a highly competitive “Clusters4Future” competition.
For more information please visit:
https://www.perkinelmer.com/category/drug-discovery-screening-solutions and https://aktuelles.uni-frankfurt.de/englisch/proxidrugs-project-led-by-goethe-university-included-in-clusters4future-programme/.
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the well-being and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.